You are here: Industry Insights > Merck

News List

Feds to back Merck at Supreme Court in Fosamax pre-emption case fiercepharma
December 06, 2018
On Monday, SCOTUS agreed to let the feds participate in the oral arguments.
FDA breakthrough designation for Bayer and Merck & Co’s AI software pharmaphorum
December 06, 2018
Bayer and Merck & Co have won a breakthrough device designation from the US regulator FDA for artificial intelligence software they are jointly developing.
P&G completes Merck’s Consumer Health unit acquisition for $3.8bn pharmaceutical-technology
December 04, 2018
Procter & Gamble (P&G) has completed its acquisition of Merck’s Consumer Health business in a €3.4bn ($3.8bn) deal.The acquisition was announced in April......
Merck secures EC approval for Delstrigo and Pifeltro indications pharmaceutical-technology
November 30, 2018
The European Commission has granted approval to Merck for its indications Delstrigo and Pifeltro to treat adults with HIV-1.Delstrigo is a new once-daily......
Evelo Enters into Clinical Trial Collaboration with Merck americanpharmaceuticalreview
November 28, 2018
Evelo Biosciences has entered into a clinical trial collaboration agreement with Merck. The collaboration will evaluate EDP1503 in combination ....
Pfizer, Merck KGaA's Bavencio flunks ovarian cancer trial fiercepharma
November 26, 2018
Monday, the drugmakers reported that their immuno-oncology drug had failed a phase 3 trial in previously treated ovarian cancer patients, failing to stave off cancer progression or prolong life either on its own or in tandem with chemo.
Merck and Palantir to form JV to advance cancer research pharmaceutical
November 21, 2018
Merck has signed a non-binding term sheet to establish a joint venture (JV) with data analytics firm Palantir Technologies to support the advancement of cancer research.
Merck and Pfizer chalk up another fail for Bavencio pharmaphorum
November 21, 2018
Merck KGaA and Pfizer’s late entrant to the checkpoint inhibitor category has failed a phase III trial in ovarian cancer, denting their hopes of building momentum for the product.
Merck KGaA and Pfizer's Bavencio falls short in ovarian cancer pharmafile
November 21, 2018
Merck KGaA and Pfizer’s Bavencio (avelumab) has missed its primary endpoints in the treatment of platinum-resistant or -refractory ovarian cancer, whether as a monotherapy or in combination with chemotherapy.
Merck and Pfizer provide update on avelumab in platinum-resistant/refractory ovarian cancer worldpharmanews
November 21, 2018
Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD)

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page